R&D Pipeline (February 2012)
R&D Pipeline (February 2012) 1. Global Development (1) Filed Code No. Generic Name Classification Therapeutic Target Area / Phase Dosage Form Origin Remarks YM178 mirabegron ASP9226 Neuropathic pain Oral In-house ASP9603 Prostate cancer Oral In-house ... Fetch Doc
GlaxoSmithKline - Product Development Pipeline
681323 p38 kinase inhibitor neuropathic pain (also atherosclerosis, COPD & rheumatoid II arthritis) 683699† dual alpha4 integrin antagonist (VLA4) multiple sclerosis II 742457 5HT6 antagonist dementia II Product Development Pipeline February 2007 ... Fetch Doc
Development Pipeline - Astra Zeneca Annual Reports
AZD2423 CCR2b antagonist chronic neuropathic pain II 4Q 2010 AZD3480# alpha4/beta2 neuronal nicotinic receptor agonist * Added to pipeline table after starting Phase II in January 2012. AstraZeneca Annual Report and Form 20-F Information 2011 ... Visit Document
PPT Template - UCB | Aspiring To Be The Patient-centric ...
By Pfizer Solid CNS & immunology pipeline Key projects CNS Expansion in our core area Epilepsy Vimpat® brivaracetam Parkinson's disease (PD) Neupro® Restless legs syndrome (RLS) Neupro® Diabetic neuropathic pain (DNP) ... Retrieve Full Source
Zonisamide - Wikipedia, The Free Encyclopedia
Elan illegally marketed Zonegran to low-income and foster children for treatment of neuropathic pain, obesity, headaches and a variety of psychiatric conditions. The case is United States ex rel. Lee Chartock v. Elan Corp., 04-cv-11594, ... Read Article
User:Kukyle/sandbox4 - Wikipedia, The Free Encyclopedia
The neuropathic pain/fibromyalgia drug Lyrica ; the oral antifungal medication Diflucan (fluconazole), the long Furthermore, internal contributions to the pipeline did not replace declining value nor did these M&A activities. ... Read Article
Fibromyalgia Drugs - Learn About Fibromyalgia Drugs
There, it's used to treat pain from several sources, including surgery, cancer, trauma and liver disease. Adeona, however, hopes to show that it treats more than just the pain of FMS, but improves mood, fatigue, cognitive problems, ... Read Article
WH Ireland - NeuroDiscovery | Home
Treatment of neuropathic pain. ASX listed NDL has a tight share structure (36 million shares issued of which only 14 million can be traded, the rest are in maturing pipeline of compounds for the treatment of neuropathic pain, which ... Fetch Full Source
Feb11 Pipeline Update
Central Neuropathic Pain due to Spinal Chord Injury Phase 3 Lyrica Alpha-2 Delta Ligand Peripheral Neuropathic Pain (U S ) Phase 3 Pfizer Pipeline – February 28, 2011 (cont’d) Neuroscience & Pain Delta Ligand Peripheral Neuropathic Pain (U.S.) Phase 3 ... Retrieve Here
Product Development Pipeline
COPD, neuropathic pain & rheumatoid arthritis) 856553 p38 kinase inhibitor atherosclerosis (also COPD, depression & rheumatoid arthritis) ll Product Development Pipeline February 2008 Phase I Phase II Phase III Filed/Approved 681323 856553 ... Access Full Source
AstraZeneca Development Pipeline - AstraZeneca In Österreich
AstraZeneca Development Pipeline 27 January 2011 Line Extensions Compound Mechanism Area Under Investigation Phase Estimated Filing neuropathic pain II AZD2066 metabotropic glutamate receptor 5 antagonist major depressive disorder II ... View This Document
DARA BioSciences To Present At The 6th Annual OneMedForum Conference
DARA BioSciences, Inc. , a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today the Company will be presenting at the 6th Annual OneMedForum to be held at the Sir Francis Drake Hotel in San Francisco. ... Read News
PURDUE PHARMA L.P. ANNOUNCES A GLOBAL STRATEGIC ALLIANCE WITH ...
PROGRAMS IN ONCOLOGY AND NEUROPATHIC PAIN Stamford, CT, USA – November 20, 2008 – Purdue Pharma L.P. and Mundi pharma International The alliance will focus on supporting Infinity’s pipeline of novel, small molecule oncology drug candidates, including IPI-926, ... Read Here
Annual Report 2007 - Newron :: Home
Neuropathic pain enabling us to rapidly plan for US and global development. In October, we pipeline of three compounds in various phases of clinical development and one discovery programme: HF0220: a broadspectrum neuroprotective agent with ... Visit Document
Merz North America (Merz Aesthetics, Inc. And Merz Pharmaceuticals, LLC) Announces The End Of Court-Ordered Injunction
Merz North America announces that effective today, January 9, 2013, the court-ordered injunction has been lifted and patients ... Read News
Pipeline
Pipeline Product Description To prevent preterm birth in women with a history of preterm delivery May 4, 2006 disorder and diabetic peripheral neuropathic pain. Indication(s) Submission Date Oral - capsule, delayed-release Route of Administration ... Read Content
Evolution In The Pain Therapy Market - Pharmaceutical ...
What’s in the Pipeline? .. 14 Opioid Abuse Deterrents Central neuropathic pain following spinal cord injury ... Access Document
Marktanalyse - Postherpetic Neuralgia Pipeline Review, H2 2012
Diabetic Neuropathic Pain – Pipeline Review, H2 2012 General Anxiety Disorder – Pipeline Review, H2 2012 Japanese Encephalitis – Pipeline Review, H2 2012 Mania – Pipeline Review, H2 2012 Neurology – Pipeline Review, H2 2012 ... Read Full Source
Facot Chemicals Presenta FACOT SERVICE - YouTube
24:13 Watch Later Error Water Supply & Water Treatment: "Pipeline to the Clouds" 1951 General Electric 25min by webdev17 246 views; 4:29 Watch Later Error Mast cell and glia cell in neuropathic pain and its treatment by chronicpaincoalition 1,369 views; ... View Video
The Global Market For Pain Management Drugs And Devices
NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: The Global Market for Pain Management Drugs and Devices http://www.reportlinker.com/p01080064/The-Global-Market-for-Pain-Management-Drugs-and-Devices.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_MedicineINTRODUCTIONSTUDY ... Read News
Research And Development At Shionogi March 22, 2012
Anti-neuropathic pain drug: S-117957 Cancer peptide vaccine: S-488210 Anti-severe infectious disease drug (Gram-negative): S-649266 Achievement in FY2011 (Non-cancer pain) Research Development Pipeline Enrichment (as of March 2012) S-877503 (ADHD) ... Retrieve Here
-Leveraging Our Strengths To Grow-
Achieved many alliances that have Achieved many alliances that have helped bolster the pipeline and productshelped bolster the pipeline and products Qutenza Peripheral neuropathic pain in non-diabetic adults Qutenza Peripheral neuropathic pain in non-diabetic adults VIBATIV cSSTI: Complicated Skin and ... Retrieve Doc
Pipeline
Pipeline Phase III Clinical Trials Positive Data for Vitrase® Management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures August 22, 2005 ... Access Doc
Parkinson's disease and phase II development of Ralfinamide for neuropathic pain. “Newron’s unique approach in the treatment of Parkinson’s disease and other of the potential of our pipeline. These funds will allow us to rapidly progress our ... Read Here
Pipeline (as Of November 2012)
Pipeline (as of November 2012) Areas Code No. (Generic name) Neuropathic pain USA: Phase I Shionogi/Purdue Pharma L.P. (USA) Shionogi/Purdue Pharma L.P. S-120083 Analgesic agent for inflammatory pain (Oral) Inflammatory pain Japan: Phase I Shionogi/Purdue ... Read Full Source
Research And Development At Shionogi March 22, 2012
Anti-neuropathic pain drug: S-117957 Cancer peptide vaccine: S-488210 Anti-severe infectious disease drug (Gram-negative): (Non-cancer pain) Research Development Pipeline Enrichment (as of March 2012) 15 Medicines Thoroughly Fight Against Disease ... Document Viewer
August 9, 2012 Pipeline Update Final
-Lyrica for treatment of central neuropathic pain due to spinal cord injury 4 Pipeline represents progress of R&D programs as of May 10, 2012 ►PF-06273340 Acute and Chronic Pain Phase 1 Pfizer Pipeline – August 9, 2012 (cont’d) ... Fetch This Document
No comments:
Post a Comment